Nom du produit:1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethan-1-amine
IUPAC Name:1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethan-1-amine
- CAS：2883543-53-9
- Formule moléculaire：C11H8F5NO
- Pureté：95%+
- Numéro de catalogue：CM1046373
- Poids moléculaire：265.18
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2883543-53-9
- Formule moléculaire:C11H8F5NO
- Point de fusion:-
- Code SMILES:CC1=C(OC2=C(F)C=C(F)C=C12)C(N)C(F)(F)F
- Densité:
- Numéro de catalogue:CM1046373
- Poids moléculaire:265.18
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Benzofurans
- Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.
- Benzofuran | C8H6O | CID 9223 -Chemenu
- Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans
- Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.
Column Infos
- STX-478
- Scorpion presented initial, first-in-human clinical results from its Phase 1/2 study of STX-478 in advanced solid tumor patients in a Proffered Paper late-breaking session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Initial Phase 1 monotherapy data for STX-478, an oral, once-daily, mutant-selective, allosteric PI3Kα inhibitor, demonstrated potentially best-in-class PI3Kα inhibition, with anti-tumor activity observed in multiple cancer types, including HR+/HER2- breast cancer (BC), gynecological tumors, and other solid tumors. STX-478 was well-tolerated, including in pre-diabetic, diabetic and heavily pre-treated patients and showed no significant wild-type-mediated toxicities.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
